CD80 (CD80 Molecule)

Collectively, BHB lowers pro-inflammatory monocyte marker expression ex vivo and dose-dependently reduces TNF-α production in LPS-stimulated whole blood and monocyte cultures. These effects appear to be partly mediated by acidification of the extracellular environment.

The present review aims to provide a complementary update, focusing specifically on recent advances in understanding how hyperthermia regulates the expression of these newer targets, as well as preclinical evidence for combining hyperthermia with novel therapeutic agents targeting these molecules. The insights gained from these preclinical studies could serve as a valuable foundation for future experimental investigations and clinical translation.

CD86high CD8+ T cells constitute a distinct immunoregulatory subset in cancer. Their differentiation is driven by an IL-12-IRF5 program, and their crosstalk with DCs via CD86/CTLA-4 engagement promotes tolerogenic remodeling of the TME. Targeting CD86 on CD8+ T cells may disrupt this suppressive circuit and potentiate antitumor immunity.

Furthermore, these compounds successfully reduced cytokine secretion in primary human tumor-PBMC and epithelial tissue co-culture models. This study validates PyRMD2Dock as a highly scalable, effective protocol for mining massive chemical libraries to discover small-molecule modulators of challenging immune receptor interfaces.

Ferroptosis downregulated the transcription of CD155 and galectin-9 in glioma cells, but inhibition of extracellular acetyl-HMGB1 reversed the effect of ferroptosis on the downregulation of galectin-9 transcription. In conclusion, ferroptosis downregulates galectin-9 transcription via extracellular acetyl-HMGB1, thereby inhibiting the biological behavior of glioma cells.

rFIP-nha inhibited tumour growth in two distinct ways, by targeting tumour cells directly and by directing macrophage polarization towards a tumour inhibitory phenotype. This dual bioactivity makes FIP-nha interesting as an additive support in cancer immunotherapy.

Here, we report a novel hybrid nanoplatform (HEV) for synergistic chemo-immunotherapy, constructed by integrating honeysuckle-derived vesicle-like nanoparticles (HDVN) with paclitaxel (PTX)-loaded liposomes via PEG-mediated fusion...miRNA sequencing and KEGG pathway analysis confirmed the cross-kingdom immunomodulatory function of HDVN, contributing to the synergistic therapeutic effect. This study establishes HDVN and HEV as a pioneering nanoplatform for targeted chemo-immunotherapy in glioma, offering a promising strategy with potential for clinical translation.

By applying time stamping to a mouse model of unmutated CLL, we demonstrate that leukemic expansion is driven by B-1 clones that arise prior to postnatal day 10. Importantly, B-1 cells in mice and humans share molecular features with unmutated CLL, altogether supporting a potential contribution of ELO B cells to this disease.

The latter might be secondary to cotrimoxazole use in the HEU infants while the altered cytokine levels might be indicative of altered immune programing. In summary, this cohort study showed that maternal HIV status has a transient effect on basal infant T-cell and monocyte activation, regulation, and monocyte responsiveness, which dissipates at 6 months of age, while altered cytokine levels persisted.

Foslip-PDT was effective in reprograming M2 macrophages to tumor-killing M1 macrophages. This study opens the way to combine direct tumor damage with TME modulation.

In preclinical cancer models, intravenous administration of YbNano potentiated the efficacy of anti-PD-L1 therapy in B16F10 melanoma-bearing C57BL/6 mice and enhanced the therapeutic outcomes of doxorubicin or anti-PD-L1 treatment in suppressing lung metastasis in 4T1 breast cancer-bearing BALB/c mice. YbNano functions as a dual activator of cGAS/STING and TLR9, orchestrating dendritic cell activation and amplifying downstream innate and adaptive immune responses in tumor microenvironment. Collectively, these findings suggest that YbNano represents a rationally engineered, multifunctional nucleic acid-based immunotherapeutic agent with the potential to modulate the tumor microenvironment and to augment responses when used in combination cancer therapy.

The LUT@POP-FH-Mn synergistically combines natural compounds and metal ions, improving drug delivery and efficacy through integrated chemotherapy, CDT, and immunotherapy. This work provides an innovative model for modernizing traditional Chinese medicine and demonstrates the promise of natural product-based nanomedicine for combined cancer therapy.